Lung Cancer Non-small Cell Stage IV Clinical Trial
Official title:
Phase II Clinical Study of Almonertinib in Combination With Lastet in the First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With EGFR Mutations
The goal of this clinical trial is to test in Locally Advanced or Metastatic Non-small Cell Lung Cancer patients with EGFR Mutations. The main question it aims to answer is: Evaluation of the Efficacy and Safety of Aumolertinib in Combination with Lastet for the Treatment of EGFR-Mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer in First-line Therapy. Participants will be treated with a combination of Aumolertinib and Lastet.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03866980 -
A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer
|
Phase 3 | |
| Recruiting |
NCT03692442 -
Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform
|
||
| Recruiting |
NCT03769103 -
Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC
|
Phase 2 | |
| Terminated |
NCT02129699 -
Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy
|
Phase 3 | |
| Recruiting |
NCT05127382 -
Osimertinib as 1st Line Therapy for Patients With Advanced EGFR Positive Non-Small Cell Lung Cancer
|
||
| Completed |
NCT03866993 -
A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer
|
Phase 3 | |
| Not yet recruiting |
NCT04184921 -
Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients
|